The Catalyst

Collaboration for Cures: Teaming Up to Advance Science and Save Lives

Posted by Tina Stow on March 26, 2015 at 3:39 PM

“Whether it’s our family, our friends, all of us are potentially patients one day.”

In a single sentence, Dr. Anthony Coyle, senior vice president and chief scientific officer at Pfizer’s Centers for Therapeutic Innovation (CTI), sums up what inspires the researchers and scientists fueling progress at America’s biopharmaceutical companies.

Read More

Topics: Science, Pfizer, NIH, clinical research

Ask About Adherence – Q&A with Prescriptions for a Healthy America

Posted by Samantha Dougherty on March 26, 2015 at 1:06 PM

Ask About Adherence is a blog series featuring Q&A’s with experts on medication adherence. In this post, we speak with Joel White, Prescriptions for a Healthy America president, on the landscape of potential solutions to non-adherence.

Read More

Topics: adherence, #Adherence123s, Ask About Adherence

Supporting Better Patient Outcomes Through Reform

Posted by Holly Campbell on March 25, 2015 at 12:49 PM

Today’s events at the White House and U.S. Department of Health and Human Services (HHS) highlighted the growing interest from policy makers and stakeholders in shifting the health care payment system to support greater quality of care rather than the quantity of care provided to patients.  PhRMA has long supported policies to advance affordable, high-quality, individualized care, and we were pleased to participate in today’s inaugural meeting of the Learning and Action Network (LAN), an initiative of HHS to discuss payment and delivery reform.

Read More

Topics: Value

Healthy Outlook: Conquering Cancer in the 21st Century

Posted by Randy Burkholder on March 25, 2015 at 12:30 PM

We are at a pivotal juncture in cancer care. As highlighted in recent stories from outlets such as The New  York Times, NPR and TIME, advances in science and technology (such as genomics and health information technology) are opening up new opportunities for effectively treating cancer.   Continuing advances in prevention, detection, and treatment are driving up cancer survival rates and enabling people to live longer and healthier lives.  At the same time, we’re in the midst of an important debate about the affordability and cost of cancer care, as well as significant changes in how we pay for and deliver care to cancer patients.

Read More

Topics: cancer

PhRMA Statement on Energy & Commerce Health Subcommittee 340B Hearing

Posted by Allyson Funk on March 24, 2015 at 7:00 AM

Today, PhRMA CEO John J. Castellani sent the following statement for the record to the Energy and Commerce Health Subcommittee on the hearing they’re holding on the 340B program:

Read More

Topics: 340B, House Energy & Commerce Committee

A Life-Saving Life’s Work: A Story on the Impact of Clinical Trials

Posted by Guest Contributor on March 23, 2015 at 4:16 PM

Clinical trials are an essential step in the process to develop new medicines and as they work to bring about lifesaving new treatments, they also contribute to the local economies where they are conducted. In partnership with PhRMA, Battelle produced a new study on the impact of biopharmaceutical-sponsored clinical trials in all 50 states.

Read More

Topics: Economic Impact, Clinical Trials

Medicare Monday: A Short Video on Medicare Part D

Posted by Allyson Funk on March 23, 2015 at 1:40 PM

Medicare Part D provides nearly 40 million older Americans and people living with disabilities with affordable access to prescription drug coverage.

There’s a lot of information out there on the Part D program and its success. To help people better understand how the program helps save money and keep beneficiaries healthy, check out our new video that highlights the five things you should know about Part D.

Read More

Topics: Part D, Medicare

Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending

Posted by Mark Grayson on March 23, 2015 at 11:53 AM

The biopharmaceutical industry comes out on top as the country’s manufacturing leader in innovation and economic contributions in a new report from ndp | analytics.

According to the analysis, the industry had the highest research and development (R&D) investment over the last decade, accounting for 27 percent of average annual R&D spending from 2000-2012. At 25 percent, the industry also had the highest growth rate in this area.

Read More

Topics: Economic Impact, IP, investment in the industry

Costs and Consequences of Not Treating High Cholesterol

Posted by Holly Campbell on March 20, 2015 at 12:44 PM

High cholesterol itself is not a disease, but it can lead to serious health consequences. Every 39 seconds, an American adult dies from a heart attack, stroke, or related vascular disease. These conditions claim the lives of more than 800,000 Americans each year with 150,000 of them under age 65. For those who do survive a heart attack or stroke, many are faced with serious illness, disability, and decreased quality of life. Despite being largely preventable, high cholesterol is a main risk factor for heart disease. 

Read More

Topics: drug cost, high cholesterol, Costs & Consequences

Which 340B Entities Are Getting Most of the Savings?

Posted by Lori Reilly on March 19, 2015 at 1:23 PM

When policymakers think about the 340B program, they often think of the thousands of clinics that depend on the 340B program to help underserved populations. The 340B program requires pharmaceutical manufacturers to provide these clinics and other qualifying entities with medicines at steep discounts.

Read More

Topics: Patients, ACA, 340B, Medicare, Medicaid, hospitals, 340B Spotlight

Personalized Updates

Posts by Topic

see more